Literature DB >> 14557628

Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency.

Fang Lu1, Jing Zhou, Andreas Wiedmer, Kevin Madden, Yan Yuan, Paul M Lieberman.   

Abstract

The switch from latent to lytic infection of Kaposi's sarcoma-associated herpesvirus is initiated by the immediate early transcriptional activator protein Rta/open reading frame 50 (ORF50). We examined the transcriptional regulation of the ORF50 core promoter in response to lytic cycle stimulation. We show that the ORF50 promoter is highly responsive to sodium butyrate (NaB) and trichostatin A (TSA), two chemicals known to inhibit histone deacetylases. The NaB and TSA responsive element was mapped to a 70-bp minimal promoter containing an essential GC box that binds Sp1/Sp3 in vitro and in vivo. Micrococcal nuclease mapping studies revealed that a nucleosome is positioned over the transcriptional initiation and the Sp1/3 binding sites. Stimulation with NaB or TSA increased histone acetylation and restriction enzyme accessibility of the ORF50 promoter transcription initiation site. Chromatin immunoprecipitation assay was used to demonstrate that the ORF50 promoter is associated with several different histone deacetylase proteins (including HDAC1, 5, and 7) in latently infected cells. NaB treatment led to the rapid association of Ini1/Snf5, a component of the Swi/Snf family of chromatin remodeling proteins, with the ORF50 promoter. Ectopic expression of the CREB-binding protein (CBP) histone acetyltransferase (HAT) stimulated plasmid-based ORF50 transcription in a HAT-dependent manner, suggesting that CBP recruitment to the ORF50 promoter can be an initiating event for transcription and viral reactivation. Together, these results suggest that remodeling of a stably positioned nucleosome at the transcriptional initiation site of ORF50 is a regulatory step in the transition from latent to lytic infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557628      PMCID: PMC229253          DOI: 10.1128/jvi.77.21.11425-11435.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

2.  Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1.

Authors:  D Y Wu; G V Kalpana; S P Goff; W H Schubach
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.

Authors:  X J Yang; V V Ogryzko; J Nishikawa; B H Howard; Y Nakatani
Journal:  Nature       Date:  1996-07-25       Impact factor: 49.962

4.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

5.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.

Authors:  E Cesarman; P S Moore; P H Rao; G Inghirami; D M Knowles; Y Chang
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

6.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

7.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

8.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

9.  Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients.

Authors:  L Morfeldt; J Torssander
Journal:  Scand J Infect Dis       Date:  1994

10.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  98 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

2.  A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication.

Authors:  Yiyang Xu; David P AuCoin; Alicia Rodriguez Huete; Sylvia A Cei; Lisa J Hanson; Gregory S Pari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA.

Authors:  Lai-Yee Wong; Angus C Wilson
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency.

Authors:  Janice M Moser; Jason W Upton; Kathleen S Gray; Samuel H Speck
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.

Authors:  Sofia Corte-Real; Chris Collins; Frederico Aires da Silva; J Pedro Simas; Carlos F Barbas; Yuan Chang; Patrick Moore; Joao Goncalves
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

6.  ICP0 and the US3 protein kinase of herpes simplex virus 1 independently block histone deacetylation to enable gene expression.

Authors:  Alice P W Poon; Haidong Gu; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

7.  Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.

Authors:  Jianping Xie; Adetola Olalekan Ajibade; Fengchun Ye; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2007-10-26       Impact factor: 3.616

8.  During lytic infections, herpes simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes.

Authors:  Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

9.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.